Table of contents

List of Figures xii
List of Tables xvi
List of Equations xviii
Symbols xix
Preface xxiii
Chapter 1. Introduction 26
1.1. Overview of *Pleurotus* mushroom 26
1.1.1. Mushroom: A historical journey from 'culinary delicacy' to 'medicinal value' 26
1.1.2. *Pleurotus* mushroom 27
1.1.3. Anti-cancer potential of *Pleurotus* mushroom 29
1.1.4. Anti-cancer potential bioactive myco-metabolites from *Pleurotus* mushroom 35
1.1.4.1. Higher molecular weight bioactive myco-metabolites 35
1.1.4.2. Lower molecular weight bioactive myco-metabolites 36
1.1.5. Explored mechanistic pathway for anti-cancer potential of *Pleurotus* mushroom 37
1.2. Overview of chemometric 39
1.3. Overview of network pharmacology 39
1.4. Rationale & Objectives 41
Chapter 2. Bioactivity-based screening of different species of *Pleurotus* mushroom with their myco-chemical profiling 44
2.1. Background 44
2.2. Objectives 46
2.3. Experimental work 46
2.3.1. Material, Chemicals, and Reagents 46
2.3.2. Extraction 47
2.3.3. Qualitative myco-chemical analysis 48
2.3.4. Quantitative myco-chemical analysis 48
2.3.4.1. Estimation of total phenolics 48
2.3.4.2. Estimation of total flavonoids 48
2.3.4.3. Estimation of total protein content 48

2.3.4.4. Estimation of total carbohydrates content 49
2.3.5. *In-vitro* cytotoxic activity 49
2.3.6. *In-vitro* free radical scavenging activity 50
2.3.6.1. DPPH assay 50
2.3.6.2. $ABTS^{\cdot+}$ assay 50
2.3.7. HPTLC-based method development, validation, and quantification of ergosterol content 51
2.3.7.1. Preparation of standard and sample solution 51
2.3.7.2. Chromatographic operative condition 51
2.3.7.3. Method validation 52
2.3.7.3.1. Calibration curve 52
2.3.7.3.2. Specificity 52
2.3.7.3.3. Sensitivity 52
2.3.7.3.4. Precision 52
2.3.7.3.5. Accuracy 53
2.3.7.4. Quantification of ergosterol in the crude extract 53
2.4. Results and discussion 53
2.4.1. Extraction yield 53
2.4.2. Qualitative myco-chemical analysis 54
2.4.3. Quantitative myco-chemical analysis 54
2.4.4. *In-vitro* cytotoxic activity 56
2.4.5. *In-vitro* free radical scavenging activity 58
2.4.6. HPTLC-based method development, validation, and quantification of ergosterol content 62
2.5. Summary 67
Chapter 3. Chemometric-based analysis of myco-metabolite of bioactive enriched fraction of *Pleurotus osteratus* and its correlation with *in-vitro* cytotoxic activity 69
3.1. Background 69
3.2. Objectives 70
3.3. Experimental work 70
3.3.1. Material, Chemicals, and Reagents 70
3.3.2. Authentication 70
3.3.2.1. Molecular characterization 70
3.3.2.2. Taxonomical characterization 71
3.3.3. Bioassay guided fractionation 72
3.3.4. *In-vitro* cytotoxic activity 72

3.3.5. LC-MS/MS-based quantitative profiling of phenolic acids, flavonoids, and ergosterol .. 73
3.3.6. LC-QTOF/MS-based untargeted myco-metabolite profiling 74
3.3.7. Chemometric analysis 75
3.3.8. Headspace Gas Chromatography (GC-HS) based solvent residual analysis 75
3.4. Result and discussion 75
3.4.1. Authentication 75
3.4.1.1. Molecular characterization 75
3.4.1.2. Taxonomical characterization 77
3.4.2. *In-vitro* cytotoxic activity 79
3.4.3. LC-MS/MS-based quantitative profiling of phenolic acids, flavonoids, and ergosterol 82
3.4.4. LC-QTOF/MS-based untargeted myco-metabolite profiling 84
3.4.5. Chemometric analysis 90
3.4.6. Headspace Gas Chromatography (GC-HS) based solvent residual analysis 95
3.5. Summary 95
Chapter 4. Tracing the anti-cancer mechanism of HFPO1 by the integrative approach of network pharmacology and experimental studies 98
4.1. Background 98
4.2. Objectives 99
4.3. Experimental work 99
4.3.1. Preliminary work 99
4.3.2. Network pharmacology 100
4.3.2.1. *In-silico* drug-likeness screening 100
4.3.2.2. Compound-target prediction 100
4.3.2.3. Diseases-target prediction 100
4.3.2.4. Protein-protein interaction 101
4.3.2.5. Gene enrichment analysis 101
4.3.2.6. Network layout of compound-target 102
4.3.2.7. *In-silico* molecular docking 102
4.3.2.8. *In-silico* cancer multi-omics expression study & prognostic potential .. 103
4.3.3. *In-vitro* experimental validation 104
4.3.3.1. Fluorescence microscopy 104
4.3.3.2. Immunoblot analysis 104

4.3.4. *In-vivo* experimentation 105
4.3.4.1. Experimental animals 105
4.3.4.2. Acute toxicity assessment 105
4.3.5. *In-vivo* anti-tumor efficacy in EAC (solid tumor) bearing Swiss albino mice 106
4.4. Results and Discussion 109
4.4.1. Network pharmacology 109
4.4.1.1. *In-silico* drug-likeness screening 109
4.4.1.2. Compound-target prediction 109
4.4.1.3. Diseases-target prediction 113
4.4.1.4. Protein-protein interaction 120
4.4.1.5. Gene enrichment analysis 124
4.4.1.6. Network layout of compound-target 126
4.4.1.7. *In-silico* docking interaction of hub targets and key myco-metabolites. 129
4.4.1.8. *In-silico* cancer multi-omics expression study & prognostic potential .. 131
4.4.2. *In-vitro* experimental validation 132
4.4.2.1. Fluorescence microscopy 132
4.4.2.2. Immunoblot analysis 134
4.4.3. *In-vivo* experimentation 135
4.4.3.1. Acute toxicity assessment 135
4.4.3.2. *In-vivo* anti-tumor efficacy in EAC (solid tumor) bearing Swiss albino mice 137
4.5. Summary 140
Chapter 5. Tracing the anti-cancer mechanism of EFPO1 by the integrative approach of network pharmacology and experimental studies 146
5.1. Background 146
5.2. Objectives 147
5.3. Experimental work 147
5.3.1. Preliminary work 147
5.3.2. Network pharmacology 148
5.3.2.1. In-silico drug-likeness screening 148
5.3.2.2. Compound-target prediction 148
5.3.2.3. Diseases-target prediction 148
5.3.2.4. Protein-protein interaction 149
5.3.2.5. Gene enrichment analysis 149
5.3.2.6. Network layout of compound-target 149

5.3.2.7. *In-silico* molecular docking 149
5.3.2.8. *In-silico* cancer multi-omic expression study & prognostic potential.... 150
5.3.3. In-vitro experimental validation..... 150
5.3.3.1. Fluorescence microscopy..... 150
5.3.3.2. Immunoblot analysis 150
5.3.4. *In-vivo* experimentation 150
5.3.4.1. Experimental animals 150
5.3.4.2. Acute toxicity assessment 151
5.3.5. In-vivo anti-tumor efficacy in EAC (solid tumor) bearing Swiss albino mice ……151
5.4. Results and Discussion 151
5.4.1. Network pharmacology 151
5.4.1.1. *In-silico* drug-likeness screening..... 151
5.4.1.2. Compound-target prediction 152
5.4.1.3. Diseases-target prediction..... 156
5.4.1.4. Protein-protein interaction 164
5.4.1.5. Gene enrichment analysis 168
5.4.1.6. Network layout of compound-target 170
5.4.1.7. *In-silico* docking interaction of hub targets and key myco-metabolites. 173
5.4.1.8. *In-silico* cancer multi-omic expression study & prognostic potential of selected hub target..... 175
5.4.2. *In-vitro* experimental validation..... 176
5.4.2.1. Fluorescence microscopy..... 176
5.4.2.2. Immunoblot analysis 177
5.4.3. *In-vivo* experimentation 178
5.4.3.1. Acute toxicity assessment 178
5.4.3.2. *In-vivo* anti-tumor efficacy in EAC (solid tumor) bearing Swiss albino mice ……180
5.5. Summary..... 183
Chapter 6. Summary and Conclusion 187
Reference and Bibliography 191
Appendix..... 204
Publication..... 211